154 related articles for article (PubMed ID: 34157128)
1. Time points and risk factors for RhD immunizations after the implementation of targeted routine antenatal anti-D prophylaxis: A retrospective nationwide cohort study.
Jernman R; Isaksson C; Haimila K; Kuosmanen M; Mäkikallio-Anttila K; Toivonen S; Ordén MR; Sulin K; Tihtonen K; Vääräsmäki M; Sainio S
Acta Obstet Gynecol Scand; 2021 Oct; 100(10):1868-1875. PubMed ID: 34157128
[TBL] [Abstract][Full Text] [Related]
2. Targeted routine antenatal anti-D prophylaxis in the prevention of RhD immunisation--outcome of a new antenatal screening and prevention program.
Tiblad E; Taune Wikman A; Ajne G; Blanck A; Jansson Y; Karlsson A; Nordlander E; Holländer BS; Westgren M
PLoS One; 2013; 8(8):e70984. PubMed ID: 23940682
[TBL] [Abstract][Full Text] [Related]
3. Targeted antenatal anti-D prophylaxis program for RhD-negative pregnant women - outcome of the first two years of a national program in Finland.
Haimila K; Sulin K; Kuosmanen M; Sareneva I; Korhonen A; Natunen S; Tuimala J; Sainio S
Acta Obstet Gynecol Scand; 2017 Oct; 96(10):1228-1233. PubMed ID: 28718198
[TBL] [Abstract][Full Text] [Related]
4. Risk factors for RhD immunisation despite antenatal and postnatal anti-D prophylaxis.
Koelewijn JM; de Haas M; Vrijkotte TG; van der Schoot CE; Bonsel GJ
BJOG; 2009 Sep; 116(10):1307-14. PubMed ID: 19538414
[TBL] [Abstract][Full Text] [Related]
5. Incidence of maternal sensitisation to Rh(D) in Christchurch, New Zealand and reasons for prophylaxis failures.
Badami KG; Parker J; Kenny A; Warrington S
N Z Med J; 2014 Jan; 127(1388):40-6. PubMed ID: 24481385
[TBL] [Abstract][Full Text] [Related]
6. Following targeted routine antenatal anti-D prophylaxis, almost half of the pregnant women had undetectable anti-D prophylaxis at delivery.
Sørensen K; Stjern HE; Karlsen BAG; Tomter G; Ystad I; Herud I; Baevre MS; Llohn AH; Akkök ÇA
Acta Obstet Gynecol Scand; 2022 Apr; 101(4):431-440. PubMed ID: 35224728
[TBL] [Abstract][Full Text] [Related]
7. Routine antenatal anti-D prophylaxis and patient compliance with the two-dose regimen.
Chaffe B; Ford J; Bills V
Transfus Med; 2007 Oct; 17(5):399-403. PubMed ID: 17903141
[TBL] [Abstract][Full Text] [Related]
8. Routine antenatal Rhesus D immunoglobulin prophylaxis: the results of a prospective 10 year study.
MacKenzie IZ; Bowell P; Gregory H; Pratt G; Guest C; Entwistle CC
Br J Obstet Gynaecol; 1999 May; 106(5):492-7. PubMed ID: 10430201
[TBL] [Abstract][Full Text] [Related]
9. Consequences of being Rhesus D immunized during pregnancy and how to optimize new prevention strategies.
Tiblad E; Westgren M; Pasupathy D; Karlsson A; Wikman AT
Acta Obstet Gynecol Scand; 2013 Sep; 92(9):1079-85. PubMed ID: 23750781
[TBL] [Abstract][Full Text] [Related]
10. Relevance of new recommendations on routine antenatal prevention of rhesus immunization: an appraisal based on a retrospective analysis of all cases observed in two French administrative areas of 3 million inhabitants.
Boulet S; Krause C; Tixier H; Bardou M; Sagot P
Eur J Obstet Gynecol Reprod Biol; 2009 Sep; 146(1):65-70. PubMed ID: 19482403
[TBL] [Abstract][Full Text] [Related]
11. The scientific basis of antenatal prophylaxis.
Urbaniak SJ
Br J Obstet Gynaecol; 1998 Nov; 105 Suppl 18():11-8. PubMed ID: 9863973
[TBL] [Abstract][Full Text] [Related]
12. Costs and benefits of non-invasive fetal RhD determination.
Teitelbaum L; Metcalfe A; Clarke G; Parboosingh JS; Wilson RD; Johnson JM
Ultrasound Obstet Gynecol; 2015 Jan; 45(1):84-8. PubMed ID: 25380024
[TBL] [Abstract][Full Text] [Related]
13. Prevention of Rh alloimmunization.
Fung Kee Fung K; Eason E; Crane J; Armson A; De La Ronde S; Farine D; Keenan-Lindsay L; Leduc L; Reid GJ; Aerde JV; Wilson RD; Davies G; Désilets VA; Summers A; Wyatt P; Young DC;
J Obstet Gynaecol Can; 2003 Sep; 25(9):765-73. PubMed ID: 12970812
[TBL] [Abstract][Full Text] [Related]
14. One single dose of 200 microg of antenatal RhIG halves the risk of anti-D immunization and hemolytic disease of the fetus and newborn in the next pregnancy.
Koelewijn JM; de Haas M; Vrijkotte TG; Bonsel GJ; van der Schoot CE
Transfusion; 2008 Aug; 48(8):1721-9. PubMed ID: 18507749
[TBL] [Abstract][Full Text] [Related]
15. [Prevention of fetomaternal rhesus-D allo-immunization. Practical aspects].
Cortey A; Brossard Y
J Gynecol Obstet Biol Reprod (Paris); 2006 Feb; 35(1 Suppl):1S123-1S130. PubMed ID: 16495838
[TBL] [Abstract][Full Text] [Related]
16. Rhesus D alloimmunization in pregnancy from 1996 to 2015 in Iceland: a nation-wide population study prior to routine antenatal anti-D prophylaxis.
Gudlaugsson B; Hjartardottir H; Svansdottir G; Gudmundsdottir G; Kjartansson S; Jonsson T; Gudmundsson S; Halldorsdottir AM
Transfusion; 2020 Jan; 60(1):175-183. PubMed ID: 31850521
[TBL] [Abstract][Full Text] [Related]
17. [Hemolytic disease of the newborn has not vanished from Finland--routine protection of RhD negative mothers during pregnancy is justifiable].
Sainio S; Kuosmanen M
Duodecim; 2012; 128(2):151-7. PubMed ID: 22372070
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of first trimester non-invasive fetal RHD screening for targeted antenatal anti-D prophylaxis in RhD-negative pregnant women: a model-based analysis.
Neovius M; Tiblad E; Westgren M; Kublickas M; Neovius K; Wikman A
BJOG; 2016 Jul; 123(8):1337-46. PubMed ID: 26663771
[TBL] [Abstract][Full Text] [Related]
19. The economics of routine antenatal anti-D prophylaxis for pregnant women who are rhesus negative.
Chilcott J; Tappenden P; Lloyd Jones M; Wight J; Forman K; Wray J; Beverley C
BJOG; 2004 Sep; 111(9):903-7. PubMed ID: 15327602
[TBL] [Abstract][Full Text] [Related]
20. [Foetal Rhesus-D typing added to antenatal screening for infectious diseases and erythrocyte immunisation].
van der Ploeg CP; Hirschberg HJ; de Haas M; Abbink F
Ned Tijdschr Geneeskd; 2015; 159():A8315. PubMed ID: 25898866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
